Bicycle Therapeutics plc Price & Performance (BCYC)

Bicycle Therapeutics is drawing attention from Wall Street, with a consensus price target of $25 per share—over 190% above its current level. Despite reporting a net loss of $0.88 per share last quarter, seven out of ten analysts rate the stock a buy, citing anticipated revenue growth in 2025.12

Bicycle Therapeutics reported a net loss of $60.8 million for Q1 2025, with expenses rising due to increased R&D and personnel costs. Revenue reached $9.98 million, slightly surpassing analyst estimates, but collaboration income fell sharply year over year, contributing to the widened loss.34

Bicycle Therapeutics shares have experienced notable swings, gaining 1.96% on May 9 but remaining down nearly 1% over the past ten days. Technical analysis suggests the stock may decline further in the short term, with a potential 3-month target range of $3.07 to $5.83 if current trends persist.56